Thus, we also demonstrated that SB202190-induced PERK activation ameliorates amyloidogenesis in AD or PD models via mtROS production using the mitochondria-targeting antioxidant MitoTEMPO. This evidence concerns the gene EIF2AK3 and Alzheimer disease.